Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.63 |
| ▸ | CA9 | Q16790 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | ERN1 | O75460 | 2/20 | 0.46 |
| ▸ | TLR2 | O60603 | 1/20 | 0.46 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.46 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3193234 | 0.88 | CYP3A4 (0.55) | CYP3A4CA9MAPK1LMNAGAA | |
| SCHEMBL23190743 | 0.88 | CYP3A4 (0.55) | CYP3A4CA9MAPK1LMNAGAA | |
| SCHEMBL29429335 | 0.88 | CYP3A4 (0.55) | CYP3A4CA9MAPK1LMNAGAA | |
| SCHEMBL24497063 | 0.86 | CA9 (0.58) | CYP3A4CA9MAPK1LMNAGAA | |
| SCHEMBL1427664 | 0.84 | CYP3A4 (0.51) | CYP3A4CA9MAPK1LMNAGAA | |
| SCHEMBL11187909 | 0.84 | CYP3A4 (0.51) | CYP3A4CA9MAPK1LMNAGAA | |
| SCHEMBL9064266 | 0.83 | CA12 (0.63) | CYP3A4CA9MAPK1LMNACA12 | |
| SCHEMBL9752762 | 0.80 | CYP3A4 (0.78) | CYP3A4CA9MAPK1LMNAGAA | |
| SCHEMBL11176106 | 0.80 | ALDH1A1 (0.51) | CYP3A4CA9LMNAMAPTALDH1A1 | |
| SCHEMBL31197714 | 0.79 | PRKCI (0.57) | CYP3A4CA9MAPK1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2209790-B1 | EQUILIBRATIVE NUCLEOSIDE TRANSPORTER ENT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-02-17 | — | — | EP | disclosed |
| US-8263592-B2 | Equilibrative nucleoside transporter ENT1 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2012-09-11 | — | — | US | disclosed |
| US-20100280025-A1 | EQUILIBRATIVE NUCLEOSIDE TRANSPORTER ENT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-04 | — | — | US | disclosed |
| EP-2209790-A2 | EQUILIBRATIVE NUCLEOSIDE TRANSPORTER ENT1 INHIBITORS | Janssen Pharmaceutica, N.V. (BE) | 2010-07-28 | — | — | EP | disclosed |
| WO-2009062990-A2 | EQUILIBRATIVE NUCLEOSIDE TRANSPORTER ENT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280025-A1 | EQUILIBRATIVE NUCLEOSIDE TRANSPORTER ENT1 INHIBITORS | SLC29A1, SLC29A2, SLC43A3 | CYP3A4 2582/4885CA9 2611/4885MAPK1 1553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.